Illumina (ILMN) Set to Announce Earnings on Thursday

Illumina (NASDAQ:ILMN) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the company posted $0.14 EPS. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts expect Illumina to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Illumina Trading Down 1.3 %

NASDAQ ILMN opened at $123.05 on Wednesday. Illumina has a 12 month low of $89.00 and a 12 month high of $213.91. The company has a 50-day moving average of $130.80 and a 200-day moving average of $127.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $19.60 billion, a P/E ratio of -16.76 and a beta of 1.19.

Insider Activity at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ILMN shares. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Finally, TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.